Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine whether an investigational drug combination consisting of
Gemzar®, Taxotere®, and Xeloda®, (called GTX) is safe and effective in treating advanced
pancreatic cancer and to study and enhance the utility of PET scans in the evaluation of
patients with pancreatic cancer.